{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:28:27Z","timestamp":1778898507766,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.msard.2020.101952","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T20:43:42Z","timestamp":1579553022000},"page":"101952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-\u03b21a in multiple sclerosis patients"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0031-9594","authenticated-orcid":false,"given":"Giulia","family":"Mallucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-0846","authenticated-orcid":false,"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Buccafusca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Amato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Trojano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-114X","authenticated-orcid":false,"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Moscato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Plewnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Zipoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Puma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2020.101952_bib0001","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/ene.12696","article-title":"BREMSO: a simple score to predict early the natural course of multiple sclerosis","volume":"22","author":"Bergamaschi","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2020.101952_bib0002","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1177\/1352458512445941","article-title":"Immunomodulatory therapies delay disease progression in multiple sclerosis","volume":"22","author":"Bergamaschi","year":"2016","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2020.101952_bib0003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp.2006.107052","article-title":"Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score","volume":"78","author":"Bergamaschi","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2020.101952_bib0004","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1352458509360549","article-title":"Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study","volume":"16","author":"Bermel","year":"2010","journal-title":"Mult. Scler."},{"issue":"19","key":"10.1016\/j.msard.2020.101952_bib0005","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.162.19.2161","article-title":"Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review","volume":"162","author":"Galetta","year":"2002","journal-title":"Arch. Int. Med."},{"issue":"13","key":"10.1016\/j.msard.2020.101952_bib0006","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.msard.2020.101952_bib0007","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2020.101952_bib0008","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"9453","key":"10.1016\/j.msard.2020.101952_bib0009","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \"to whom do the results of this trial apply?","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2020.101952_bib0010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ana.21464","article-title":"Will Rogers phenomenon in multiple sclerosis","volume":"64","author":"Sormani","year":"2008","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.101952_bib0011","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ana.21102","article-title":"New natural history of interferon-beta-treated relapsing multiple sclerosis","volume":"61","author":"Trojano","year":"2007","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.101952_bib0012","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ana.21757","article-title":"Real-life impact of early interferon beta therapy in relapsing multiple sclerosis","volume":"66","author":"Trojano","year":"2009","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.101952_bib0013","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrneurol.2016.188","article-title":"Treatment decisions in multiple sclerosis - insights from real-world observational studies","volume":"13","author":"Trojano","year":"2017","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:48:22Z","timestamp":1761900502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820300286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":13,"alternative-id":["S2211034820300286"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.101952","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-\u03b21a in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.101952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101952"}}